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ABSTRACT 
Background 
The pathogenesis of CKD-associated anemia is multifactorial and includes 
decreased production of erythropoietin, iron deficiency, inflammation and 
erythropoietin resistance. To better understand the trajectory of these parameters 
we described temporal trends in hemoglobin (Hb), ferritin, transferrin saturation, 
C-reactive protein (CRP) and darbepoetin dosing in the Trial to Reduce 
cardiovascular Events with Aranesp Therapy (TREAT). 
 
Methods 
We performed a post-hoc analysis of 4,038 participants in TREAT.  Mixed effects 
linear regression models were used to determine the trajectory of parameters of 
interest prior to ESRD.  Likelihood ratio tests were used to test for overall 
differences in biomarker values and differences in trajectories between those 
who did and did not develop ESRD.  
 
Results 
Hb declined precipitously in the year prior to the development of ESRD 
(irrespective of treatment assignment), and was on average 1.15 g/dL (95%CI -
1.26 to -1.04) lower in those that developed ESRD vs. those that did not, at the 
time of ESRD/end of follow-up.  Simultaneously, the mean darbepoetin dose and 
CRP concentration increased, while serum ferritin and transferrin saturations 
were greater than 140 mcg/L and 20% respectively.  
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Conclusions 
Our analyses provide descriptive insights regarding the temporal changes of Hb, 
darbepoetin dose and related parameters as ESRD approaches in participants of 
TREAT. Hb declined as much as 1-2 years prior to the development of ESRD, 
without biochemical evidence of iron deficiency.  The most precipitous decline 
occurred in the months immediately prior to ESRD, despite administration of 
escalating doses of darbepoetin and in parallel with an increase in CRP.   
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Introduction 
Chronic kidney disease (CKD) affects approximately 11.5% of the general 
population[1] and 40% of those with self-reported diabetes mellitus in the United 
States.[2] Anemia (defined as hemoglobin <12 g/dL in men and <11 g/dL in 
women) is a common comorbid condition in diabetic patients with CKD and is 
estimated to affect 22% of patients with CKD Stage 3 and 52% with CKD Stage 
4.[3] The presence of anemia in CKD is associated with an increased risk of 
cardiovascular events, all-cause mortality,[4] and progression to end-stage renal 
disease (ESRD).[5]   
Progressive loss of renal function is associated with inadequate 
erythropoiesis and lowering of the blood hemoglobin concentration (Hb). Other 
factors that may contribute to the development of anemia as CKD progresses 
include iron deficiency and inflammation.[6] The introduction of recombinant 
erythropoietin (EPO) heralded a new era in nephrology, as the requirement for 
repeated blood transfusions was negated, and Hb could be maintained at near 
normal levels. [7,8] However, several studies reported that targeting ‘normal’ Hb 
levels was not associated with benefit, but rather with potential harm,[9-11] while 
a lack of responsiveness to exogenous EPO is associated with greater risk of CV 
events and death.[12] A contemporary approach that examines the sequential 
changes of Hb decline relative to markers of iron deficiency, inflammation and 
darbepoetin dosing may provide important clinical insights, building on what is 
already known in this area. 
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The repeated scheduled ascertainment of Hb, and other biomarkers, in 
the Trial to Reduce cardiovascular Events with Aranesp Therapy (TREAT)[11] 
provided an opportunity to describe the temporal trends of Hb prior to the 
occurrence of ESRD.  Furthermore, comparisons to a group of participants who 
did not develop ESRD (both in the presence and absence of randomized 
darbepoetin vs. placebo therapy) was possible.  
 
Methods 
Study design and population 
In these post-hoc and descriptive analyses, we evaluated longitudinal 
changes in biomarkers of interest (hemoglobin, ferritin, transferrin saturation, C-
reactive protein [CRP], creatinine, eGFR, urine protein/creatinine ratio [PCR] and 
average monthly darbepoetin dose) in participants of the TREAT study. The 
design and original results of TREAT (NCT00093015) have been 
published.[11,13] Briefly, TREAT was a prospective, double-blind, randomized 
controlled trial of darbepoetin alfa versus placebo for the treatment of anemia in 
4,038 participants with type 2 diabetes mellitus (T2DM), eGFR of 20-60 
mL/min/1.73m2 according to the 4-variable MDRD (Modification of Diet in Renal 
Disease) Study equation, Hb <11.0 g/dL, and transferrin saturation >15%. The 
initial dose of darbepoetin in the active treatment arm was 0.75 mcg/kg, with 
doses adjusted monthly according to a computer-based algorithm to target Hb at 
13 g/dL.  In the placebo arm, if Hb fell below 9g/dL, ‘rescue’ therapy with a single 
dose of 0.45 mcg/kg darbepoetin was given (Supplementary Figure 1).  Per 
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protocol, all participants were regularly assessed (and treated as needed) for 
serum markers of iron sufficiency (ferritin and transferrin saturation; 
Supplementary Figure 2).  All participants gave written informed consent in the 
primary trial and the serum samples used in this analysis (Partners IRB 
2005P000170). 
 
Statistical Analyses 
A contemporary descriptive analytic approach was employed, whereby 
temporal trends in biomarkers were plotted by working retrospectively from the 
time of an event of interest (i.e. ESRD).  In these analyses, the exposure variable 
for those that developed ESRD was the date of the confirmed ESRD event 
subtracted from the date of the biomarker measurement (i.e. time prior to ESRD). 
ESRD (n=668) was defined as initiation of renal replacement therapy (RRT; 
sustained for at least 30 days), initiation of RRT with death within 30 days, a 
physician recommendation to initiate RRT with documented participant refusal, or 
receipt of a kidney transplant.  The outcome variable was the measured 
biomarker of interest. Owing to right-skewed distributions, log-transformation was 
performed for ferritin, CRP, urine PCR and creatinine, and corresponding 
estimates were produced using geometric means. The CRP assay had a lower 
limit of detection of 3.0mg/L; for those with concentrations below this limit, a 
value of 1.5mg/L was imputed for these analyses.  
In order to provide meaningful comparisons, similar analyses were 
performed in a comparator group of TREAT participants who did not experience 
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ESRD during follow-up (n=3,370). For these individuals, time prior to end of 
follow-up was similarly calculated as date of the end of follow-up (EOF) 
subtracted from the date of the biomarker measurement. To ensure the follow-up 
of this group was comparable to those that developed ESRD (i.e. participants 
entered analyses at randomization, were followed for the same average duration, 
and EOF was not induced by death), a modified EOF (mEOF) was created by 
shortening the exposure duration by 310 days.  Therefore, the average duration 
between randomization and end of follow-up was identical (563 days) for both 
subgroups.  In exploratory analyses, a propensity-score algorithm (based on 
baseline age, gender, race, eGFR and urine PCR) was used to select non-ESRD 
comparators that were similar with respect to those that went on to develop 
ESRD.  
Baseline variables were summarized such that continuous variables were 
examined graphically and recorded as means (± standard deviations) for 
normally distributed data, or medians (with interquartile ranges) for non-normally 
distributed data. Categorical variables were examined by frequency distribution 
and recorded as proportions.  Tests for difference according to ESRD were 
conducted using t-tests, Wilcoxon Rank Sum tests and the Chi-square test for 
trend for continuous normal, continuous non-normal, and categorical data, 
respectively. 
Average values of biomarker measurements prior to ESRD/mEOF were 
estimated through the use of a mixed effects linear regression model, using 
participant ID’s as random effects.  To allow for potentially non-linear changes 
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over time, days prior to ESRD/mEOF was modeled using restricted cubic spline 
terms with four knots.  The relationship between time and the average biomarker 
values were modeled using interaction terms between the group indicator (ESRD 
vs. not) and the cubic spline terms representing days prior to ESRD/mEOF. From 
this model, estimates of the average difference between those that developed 
ESRD vs. those that did not were produced at 0, 1, 2, and 3 years prior to the 
ESRD/mEOF. Likelihood ratio tests were performed comparing the full model 
(with group variables and interaction terms) to: 1) models without any group 
variable or interaction terms to perform global tests for differences in biomarker 
values between groups; 2) models without any interaction terms to perform 
global tests for differences in biomarker trajectories over time.  Estimated time of 
divergence of biomarkers of interest (ESRD vs. not) was defined as the latest 
time at which the difference in point estimates became significant at α=0.01.  A 
pre-specified sub-group analysis was performed according to randomized 
treatment arm and baseline use of angiotensin converting enzyme inhibitors 
(ACEi) or angiotensin receptor blockers (ARB).   
Recognizing that the trajectories of biomarkers changed most markedly 
during the last six months prior to ESRD/mEOF, the following exploratory 
analyses were performed to explore potential associations with clinical variables 
according to development of ESRD or not: use of a more stringent biochemical 
definition of iron sufficiency (transferrin saturation >30% and ferritin >200 mcg/L); 
the proportion of participants that developed a GI bleed. For all other analyses, 
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nominal 2-sided P values of <0.05 were considered statistically significant. All 
analyses were performed using STATA 14 (College Station, Tex., USA). 
 
Results 
Baseline Characteristics 
 The primary cohort consisted of 4,038 individuals (57% women) with a 
median age of 68 years.[11] At baseline, those who ultimately developed ESRD 
were more likely to be younger, male and black, and to have a longer duration of 
T2DM and higher HbA1c compared with those that did not.  Those that 
developed ESRD were more likely to have lower baseline Hb, serum albumin, 
eGFR, and to have higher ferritin, transferrin saturation, CRP, creatinine, urine 
protein/creatinine ratio and more likely to have a history of acute kidney injury 
(Table 1).  
 
Trajectory of Hemoglobin  
In the placebo arm, three years prior to the development of ESRD/mEOF, 
Hb was similar in those that ultimately developed ESRD compared with those 
who did not (10.4 g/dL vs. 10.3g/dL; p=0.10; Table 2).  However, from the outset, 
the overall trajectory of Hb in those who went on to develop ESRD was 
downwards, with a more precipitous decline evident in the year prior to the ESRD 
event.  For those who did not develop ESRD, Hb modestly increased over time.  
In the treatment arm, Hb initially increased for both those who did and did 
not go on to develop ESRD.  However, approximately 1.6 years prior to the 
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ESRD/mEOF, the trajectories were significantly different, such that Hb continued 
to increase in those who did not develop ESRD, but declined in those who did.   
This decline was more marked in the year prior to ESRD, such that at the time of 
ESRD/mEOF the Hb was lower (1.0 g/dL; 95%CI -1.1 to -0.9 g/dL) in those with 
ESRD (Figure 1 and Table 2).  There was no evidence of difference in patterns 
according to baseline use of ACEi/ARB medications (Supplementary Figure 3).   
 
Trajectory of Darbepoetin Dosing  
 In the placebo arm (where, per protocol, only ‘rescue’ doses of 
darbepoetin were provided), in the year prior to ESRD/mEOF there was an 
increase in the average monthly dose of darbepoetin in those who went on to 
develop ESRD, compared with those who did not.  The trajectory in those that 
did not develop ESRD remained relatively flat.  The estimated time of divergence 
of the dosing trajectories was ~1.4 years prior to the time of ESRD/mEOF (Figure 
1 and Table 2).   
In the treatment arm, the average monthly dose of administered 
darbepoetin (determined by a predefined algorithm) increased steadily in all 
participants between three years and one year prior to the development of 
ESRD/mEOF. However, for those that ultimately progressed to ESRD, there was 
a notable increase in the darbepoetin dosing during the year prior to this event, 
with significant divergence of the dose trajectory occurring ~0.6 years prior to this 
event (Figure 1 and Table 2).  
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Trajectory of Ferritin  
The trajectory of serum ferritin was similar for participants in both the 
placebo and treatment arms, such that ferritin increased over time for both those 
who did and did not develop ESRD, but was always significantly higher in the 
ESRD group.  Overall, ferritin was relatively lower at each time point examined in 
the darbepoetin arm as compared with the placebo arm (Figure 2 and Table 2).  
 
Trajectory of Transferrin Saturation 
In the placebo arm, transferrin saturations were marginally higher in those 
who developed ESRD at three years prior to ESRD/mEOF, but subsequently the 
trajectories were overlapping until the months immediately preceding 
ESRD/mEOF, when the transferrin saturations declined in those that developed 
ESRD.  In the darbepoetin arm, the trajectories were overlapping and increased 
over time for both those who did and did not develop ESRD.  However, in the 
months immediately prior to ESRD/mEOF, the transferrin saturation trajectory 
declined in those that went on to develop ESRD (Figure 2 and Table 2).  
 
Trajectory of C-Reactive Protein 
In the placebo arm CRP was marginally higher in those who developed 
ESRD during the period of three years to one year prior to ESRD/mEOF.  After 
this point CRP began to markedly increase in those who went on to develop 
ESRD, with the trajectory significantly diverging ~0.6 years prior to the ESRD 
event.  In the darbepoetin arm, three years prior to the development of 
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ESRD/mEOF, CRP concentrations were similar in those who did and did not 
develop ESRD (p-difference=0.35).  During the initial follow-up, CRP increased in 
both groups, but for those that developed ESRD a more marked rise was evident 
in the year prior to the ESRD event, with the trajectories significantly diverging 
~0.4 years prior (Figure 2 and Table 2).  
 
Trajectory of Serum Creatinine, eGFR and urine protein/creatinine ratio 
The trajectories of serum creatinine and eGFR followed expected patterns 
for those who did and did not develop ESRD (Supplementary Table 1 and 
Supplementary figures 4 and 5). In contrast, there were no notable changes in 
the trajectory of urine protein/creatinine ratio in the last six months in either those 
who did or did not develop ESRD (Supplementary Table 1 and Figure 6). 
 
 
Exploratory Analyses 
Recognizing that there were baseline differences between the groups that 
did and not develop ESRD, additional analyses were performed utilizing a non-
ESRD comparator group that was matched for baseline characteristics.  Using 
this refined comparator group (n=670), the overall trajectories of hemoglobin, 
darbepoetin dose, transferrin saturation and ferritin were similar to those 
obtained from the non-ESRD comparator group in the original analyses 
(Supplementary Table 2). 
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In the year prior to ESRD/mEOF, 37% of those who developed ESRD and 
32% of those that did not (p-difference=0.01) had simultaneously transferrin 
saturations >30% and ferritin >200 mcg/L on at least one occasion. This occurred 
despite a greater proportion of GI bleeds in the 6 months prior to ESRD/mEOF 
(19 of the 28 GI bleeding adverse events [68%] in those that developed ESRD 
vs. 19 of the 91 [21%] in those that did not develop ESRD occurred during this 
period).    
 
Discussion 
 Our contemporary analytic approach (examining the temporal changes of 
Hb relative to biomarkers of iron stores, darbepoetin dosing and inflammation) 
provides incremental knowledge regarding the changes in Hb in individuals with 
CKD, anemia and T2DM.  We illustrate that these parameters follow markedly 
different trajectories in participants who did and did not develop ESRD.   
Specifically, in those who developed ESRD, Hb became progressively lower, 
despite biochemical measures suggesting iron sufficiency and the administration 
of increasing darbepoetin doses, while CRP was noted to increase.  
 The primary regulator of erythrocyte production is EPO, a 34 kDa 
glycoprotein produced predominantly by renal interstitial fibroblasts, that 
functions primarily to stimulate erythropoiesis in the bone marrow in response to 
tissue hypoxia.[14] Prior reports indicate that the development of CKD-
associated anemia is more likely related to insufficient increases in EPO 
production, rather than an absolute decline in circulating EPO levels.[15] This 
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relationship provides challenges in the interpretation of EPO levels in CKD-
associated anemia and limits their diagnostic utility; therefore, serum EPO levels 
were not measured as part of the TREAT study.  
TREAT also provided an important opportunity to examine trends in Hb in 
the setting of exogenous administration of EPO derivatives. As expected, our 
analyses of the active therapy arm indicate that administration of darbepoetin 
resulted in an increase in Hb during the early phases of treatment.  However, as 
CKD progressed over time, Hb started to decline in those who developed ESRD, 
and continued to decrease despite escalating doses of darbepoetin.   A different 
pattern was noted in the placebo arm – in participants who developed ESRD the 
Hb trajectory was downward from the beginning, and again occurred despite 
administration of escalating ‘rescue’ doses of darbepoetin. In contrast, in those 
that did not develop ESRD, Hb was relatively stable over time.  Prior data from 
our group examined participants in the placebo arm of TREAT, reporting that 
lower baseline Hb, lower eGFR and higher proteinuria were the major predictors 
for requiring ≥5 ‘rescue’ doses of darbepoetin.  Furthermore, compared with 
participants that did not receive any ‘rescue’ doses, those that received ≥5 were 
more likely to progress to ESRD.[16] Together these findings highlight that, in 
many cases, administration of increasing doses of darbepoetin (often in excess 
of 200 mcg per month) as ESRD approaches appears to be insufficient to 
prevent a continued decline in Hb.    
The most common reason for hypo-responsiveness to exogenous EPO in 
CKD patients is iron deficiency, suggested by a serum ferritin concentration <100 
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mcg/L and/or transferrin saturations <20%.[17] Results from NHANES suggest 
that up to two-thirds of patients with moderate CKD may have insufficient iron 
stores as defined by these criteria.[18] In our analyses we noted that serum 
ferritin increased over time in both those that did and did not develop ESRD, 
which may partially relate to protocol driven iron supplementation.  However, it 
was also apparent that ferritin was consistently higher in those that developed 
ESRD compared with those that did not, which could suggest a greater degree of 
underlying inflammation.  In this regard, it is notable that hepcidin (a major 
regulator of systemic iron homeostasis via its inhibitory effect on ferroportin), is 
also up regulated by inflammatory cytokines[19] and could contribute to anemia 
development.  In TREAT all participants were assessed and treated for iron 
deficiency according to a predefined study algorithm. Interestingly, we noted a 
decline in transferrin saturation in the months prior to development of ESRD that 
corresponded to a greater observed frequency of GI bleeds in those that 
developed ESRD (vs. not). However, the overall event rate was relatively small, 
while overall a greater proportion of ESRD participants actually met a more 
stringent biochemical definition of iron sufficiency during this period. However, we 
recognize that biochemical measures of iron stores may under-diagnosis 
deficiency at the bone marrow level,[20] and therefore we cannot exclude the 
possibility of a greater prevalence of iron deficiency in these participants.   
The presence of inflammation is postulated to be a major risk factor for 
EPO hypo-responsiveness, with several studies reporting an association with the 
presence of elevated inflammatory biomarkers.[21,22] Indeed, prior analyses of 
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TREAT by our group have reported that elevated levels of CRP (>3 mg/L) were 
present in 48% of participants at baseline,[23] and that CRP was marginally 
higher at baseline in those who had an impaired Hb response to darbepoetin.[12] 
Our current analyses extend these findings by examining all available CRP 
measurements during follow-up.  We report that CRP concentrations increased 
markedly in participants who went on to develop ESRD in the months prior to this 
event, compared with those that did not.  Although causality cannot be proved 
from our data, the temporal relationship with the decline in Hb in those that 
developed ESRD, in addition to increasing ferritin (also an inflammatory marker), 
provides additional support for the hypothesis of EPO hypo-responsiveness 
secondary to the presence of inflammation.   
The strengths of this study include the utilization of repeated laboratory 
measures collected in the setting of a large, randomized controlled trial.   
Concerns related to potential prescriber bias are limited by the fact that a 
computer-based dosing algorithm was utilized for all participants. However, there 
are limitations to our report.  Our analyses are primarily descriptive and do not 
allow for adjustment for potential variables that could potentially alter these 
measurements over the course of the study.  For example, hospitalizations may 
be more likely to occur in those that developed ESRD, thereby contributing to 
lower Hb from inpatient stays, while also contributing to missing data from 
outpatient study visits. The follow up time for those who did not develop ESRD 
was truncated in order to be of similar duration to those that developed ESRD.  
While this may have reduced the overall number of available measurements, 
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truncation ensured that the exposure time captured in both subgroups did not 
include any fatal events. The progression of secondary hyperparathyroidism or 
undetected/inadequately treated iron deficiency in those that develop ESRD may 
contribute to EPO hyporesponsiveness[24], but unfortunately parathyroid 
hormone and data related to the trajectory of intravenous iron therapy were not 
available. Similarly, aside from relative EPO insufficiency, other potential 
contributors to the development of anemia with progressive CKD may relate to 
accumulation of as yet unidentified uremic toxin(s). Finally, as this study was 
performed in participants with CKD, anemia and T2DM, it is unclear if the results 
are generalizable to patients without these comorbidities. 
In conclusion, we report that Hb declined rapidly in the months prior to the 
development of ESRD, coincident with a rise in CRP.  This pattern occurred in 
the absence of biochemical measures of iron deficiency and despite escalating 
doses of darbepoetin.  This constellation of findings supports the contribution of 
an increasing inflammatory state to the pathogenesis of EPO hypo-
responsiveness as CKD progresses to ESRD. Incorporation of this analytic 
approach, which provides additional insight to the temporal changes in 
biomarkers approaching an event of interest, may help to uncover further 
pathophysiologic changes that contribute to the progression of CKD.   
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 1 
Table 1.   
 ESRD  
(N=668) 
Non-ESRD 
(N=3,370) 
Pa 
Age (years) 63.6 ±10.6 68.1 ±10.5 <0.001 
Male (%) 54.8 40.4 <0.001 
Race (%)   <0.001 
     Black 27.7 18.7  
     Hispanic 15.7 12.8  
     Other 2.7 2.9  
     White 53.9 65.6  
    
Hemoglobin (g/dL) 10.2 ±1.0 10.4 ±1.0 <0.001 
Ferritin (mcg/L) 175 [95-315] 126 [63-248] <0.001 
Transferrin Saturation 
(%) 
25.5 ±9.9 24.0 ±9.3 <0.001 
Iron therapy (%) 46.0 43.7 0.29 
Treatment 
(Darbepoetin vs. 
Placebo, %) 
50.6 49.7 0.66 
    
Creatinine (mg/dL) 2.5 [2.1-3.0] 1.8 [1.5-2.2] <0.001 
eGFR (mL/min/1.73m2) 23 [19-29] 33 [26-42] <0.001 
Urine Pr/Cr ratio 2.7 [0.9-5.7] 0.3 [0.1-1.1] <0.001 
CRP (mg/L)b 3.3 [Ub-7.3] Ub  [Ub-6.5] 0.01 
    
Albumin (g/dL) 3.7 ±0.5 4.0 ±0.4 <0.001 
History of AKI (%) 13 9 <0.001 
Duration of T2DM 
(years) 
16 [10-22] 15 [8-22] <0.001 
HbA1c (%) 7.2 [6.4-8.2] 6.9 [6.2-7.9] <0.001 
ACEi/ARB therapy (%) 78.7 80.0 0.45 
a P value for difference; significance testing was by t test or Wilcoxon rank sum 
test for continuous variables or chi-squared test for categorical variables. 
Continuous variables are presented as means ±standard deviation if normally 
distributed or medians [25th to 75th percentiles] if non-normally distributed.  
Abbreviations: eGFR, estimated glomerular filtration rate; Pr/Cr, protein to 
creatinine ratio; CRP, C-reactive protein; U, undetectable; AKI, acute kidney 
injury; T2DM, type 2 diabetes mellitus; HbA1c, glycated hemoglobin; ACEi/ARB, 
angiotensin converting enzyme inhibitor/angiotensin receptor blocker  
 
b The lower limit of detection for baseline CRP was 3 mg/L 
 2 
Table 2.   
Comparison of Biomarkers in those that develop ESRD (n=668) vs. Not (n=3,370) 
 Time Prior to ESRD/Modified End of Follow-up P-values 
Biomarker 3 years 2 years 1 year Time of 
ESRD/mEnd 
of Follow-up 
Estimated 
Time of 
Divergencea 
Equality Interaction 
 Placebo Group    
 ESRD vs. not 
(P-difference) 
ESRD vs. not 
(P-difference) 
ESRD vs. not 
(P-difference) 
ESRD vs. not 
(P-difference) 
   
Hemoglobin (g/dL) 10.4 vs 10.3; 
p=0.10 
10.3 vs 10.5; 
p=0.001 
10.2 vs 10.7; 
p<0.001 
9.5 vs 10.9; 
p<0.001 
2.1 years <0.001 <0.001 
Darbepoetin  
(Mean Dose in mcg/month) 
1.3 vs 3.9; 
p=0.019 
3.2 vs 3.4; 
p=0.82 
7.4 vs 3.3; 
p<0.001 
18.5 vs 3.8; 
p<0.001 
1.4 years <0.001 <0.001 
Darbepoetin Dose Difference 
([ESRD – non-ESRD] in mcg/month) -2.6 -0.2 +4.1 +14.7 
1.4 years <0.001 <0.001 
Ferritin (mcg/L)b 147 vs 105; 
p<0.001 
148 vs 114; 
p<0.001 
172 vs 132; 
p<0.001 
204 vs 153; 
p<0.001 
>3 years <0.001 0.36 
Transferrin Saturation (%) 24.9 vs 22.6; 
p=0.007 
24.5 vs 24.0; 
p=0.3 
26.1 vs 25.2; 
p=0.07 
24.3 vs 26.0; 
p=0.014 
N/A <0.001 <0.001 
CRP (mg/L)b, c 3.7 vs 3.0; 
p=0.05 
3.9 vs 3.2; 
p=0.007 
3.9 vs 3.5; 
p=0.06 
5.8 vs 3.7; 
p<0.001 
0.6 years <0.001 0.006 
 Darbepoetin Group    
 ESRD vs. not 
(P-difference) 
ESRD vs. not 
(P-difference) 
ESRD vs. not 
(P-difference) 
ESRD vs. not 
(P-difference) 
   
Hemoglobin (g/dL) 11.2 vs 11.4; 
p=0.05 
11.7 vs 11.8; 
p=0.036 
11.9 vs 12.1; 
p<0.001 
11.5 vs 12.5; 
p<0.001 
1.6 years <0.001 <0.001 
Darbepoetin  
(Mean Dose in mcg/month) 
131 vs 136; 
p=0.42 
138 vs 148; 
p=0.08 
162 vs 161; 
p=0.95 
232 vs 177; 
p=<0.001 
0.6 years <0.001 <0.001 
Darbepoetin Dose Difference 
([ESRD – non-ESRD] in mcg/month) 
-5 -10 +1 +55 0.6 years <0.001 <0.001 
Ferritin (mcg/L)b 92 vs 78; 
p<0.001 
119 vs 98; 
p<0.001 
151 vs 122; 
p<0.001 
179 vs 150; 
p=0.005 
>3 years 0.002 0.73 
 3 
Transferrin Saturation (%) 22.0 vs 20.9; 
p=0.3 
25.6 vs 25.7; 
p=0.94 
29.8 vs 29.8; 
p=0.94 
29.5 vs 32.2; 
p=0.002 
0.2 years 0.008 0.005 
CRP (mg/L)b, c 2.9 vs 3.2; 
p=0.35 
3.5 vs 3.1; 
p=0.14 
3.6 vs 3.4; 
p=0.41 
5.3 vs 3.7; 
p<0.001 
0.4 years <0.001 <0.001 
P values refer to the difference in average biomarker concentrations between those that did and do not develop ESRD at specific time points (time 
of event or end of follow-up; 1 year prior; 2 years prior; or 3 years prior).  Equality tests the null hypothesis that the curves are superimposable (i.e. 
differences in biomarkers between groups); P for Interaction tests the null hypothesis that the curves are parallel (i.e. differences in biomarker 
trajectories over time).  
a Estimated time of divergence of biomarkers of interest (developed ESRD vs. not) was defined as the latest time at which the difference in point 
estimates became significant at α=0.01.   
b Groups are summarized and compared using geometric means 
c Individuals with undetectable CRP (≤3 mg/L) were assumed to have a CRP=1.5 mg/L 
Figure 1.  
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